Rx0000356 |
Radius Health, Inc. |
01/31/2025 |
70539000102 |
TYMLOS 80 MCG Pen / Carton
Injection: 3120 mcg/1.56 mL (2000 mcg/mL) in a single-patient-use prefilled
pen. The prefilled pen delivers 30 daily doses of 80 mcg abaloparatide in 40
mcL of sterile, clear, colorless solution. |
01/01/2025 |
160.02 |
2827.02 |
01/10/2040 |
Single Source Drug |
None |
None |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Radius believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administrations Orange Book, as of 10/26/2023. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Radius Health, Inc. did not acquire this product from another manufacturer within the previous five years. As a result, Radius Health has left columns N-U blank because they are not applicable to this product. |
Rx0000356 |
Radius Health, Inc. |
01/31/2025 |
70539000101 |
TYMLOS 80 MCG Pen.
Injection: 3120 mcg/1.56 mL (2000 mcg/mL) in a single-patient-use prefilled
pen. The prefilled pen delivers 30 daily doses of 80 mcg abaloparatide in 40
mcL of sterile, clear, colorless solution. |
01/01/2025 |
160.02 |
2827.02 |
01/10/2040 |
Single Source Drug |
None |
None |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Radius believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administrations Orange Book, as of 10/26/2023. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Radius Health, Inc. did not acquire this product from another manufacturer within the previous five years. As a result, Radius Health has left columns N-U blank because they are not applicable to this product. |
Rx0000363 |
Recordati Rare Diseases, inc. |
04/15/2025 |
55292041005 |
Cystadrops Ophthalmic Solution 0.37 % 1 5ml bottle |
01/01/2025 |
115.46 |
2424.65 |
None |
Single Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000363 |
Recordati Rare Diseases, inc. |
04/15/2025 |
55292032060 |
Isturisa Oral Tablet 1 MG 60 tablets |
01/01/2025 |
944.10 |
10881.98 |
10/12/2035 |
Single Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000363 |
Recordati Rare Diseases, inc. |
04/15/2025 |
55292032160 |
Isturisa Oral Tablet 5 MG 60 tablets |
01/01/2025 |
4720.49 |
54409.87 |
10/12/2035 |
Single Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000363 |
Recordati Rare Diseases, inc. |
04/15/2025 |
55292070255 |
Panhematin Intravenous Solution Reconstituted 350 MG 1 vial |
01/01/2025 |
245.97 |
10940.49 |
None |
Single Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000363 |
Recordati Rare Diseases, inc. |
04/15/2025 |
55292013901 |
Signifor LAR Intramuscular Suspension Reconstituted ER 10 MG 1 vial |
01/01/2025 |
953.38 |
20021.07 |
05/23/2028 |
Single Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000363 |
Recordati Rare Diseases, inc. |
04/15/2025 |
55292014001 |
Signifor LAR Intramuscular Suspension Reconstituted ER 20 MG 1 vial |
01/01/2025 |
953.38 |
20021.07 |
05/23/2028 |
Single Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000363 |
Recordati Rare Diseases, inc. |
04/15/2025 |
55292014101 |
Signifor LAR Intramuscular Suspension Reconstituted ER 30 MG 1 vial |
01/01/2025 |
953.38 |
20021.07 |
05/23/2028 |
Single Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000363 |
Recordati Rare Diseases, inc. |
04/15/2025 |
55292014201 |
Signifor LAR Intramuscular Suspension Reconstituted ER 40 MG 1 vial |
01/01/2025 |
953.38 |
20021.07 |
05/23/2028 |
Single Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000363 |
Recordati Rare Diseases, inc. |
04/15/2025 |
55292014301 |
Signifor LAR Intramuscular Suspension Reconstituted ER 60 MG 1 vial |
01/01/2025 |
953.38 |
20021.07 |
05/23/2028 |
Single Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000363 |
Recordati Rare Diseases, inc. |
04/15/2025 |
55292013160 |
Signifor Subcutaneous Solution 0.3 MG/ML 60 Ampules |
01/01/2025 |
1004.34 |
21091.07 |
12/14/2026 |
Single Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000363 |
Recordati Rare Diseases, inc. |
04/15/2025 |
55292013260 |
Signifor Subcutaneous Solution 0.6 MG/ML 60 Ampules |
01/01/2025 |
1004.34 |
21091.07 |
12/14/2026 |
Single Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000363 |
Recordati Rare Diseases, inc. |
04/15/2025 |
55292013360 |
Signifor Subcutaneous Solution 0.9 MG/ML 60 Ampules |
01/01/2025 |
1004.34 |
21091.07 |
12/14/2026 |
Single Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000166 |
Redhill Biopharma, Inc. |
04/17/2025 |
57841115002 |
Talicia Oral Capsule Delayed Release 250-12.5-10 MG 2 Bottles of 84 Capsules |
01/01/2025 |
24.34 |
835.73 |
02/12/2034 |
Single Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000239 |
Rigel Pharmaceuticals, Inc. |
03/31/2025 |
71332000660 |
GAVRETO 100MG 60 CAPS |
01/03/2025 |
667.42 |
11812.00 |
11/01/2036 |
Single Source Drug |
None |
None |
None |
1 |
Pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, commercial and government rebates, patient support, overall research and development costs |
None |
This WAC increase is not necessitated by a change or improvement in the prescription drug. |
None |
02/22/2024 |
BluePrint Medicines Corporation |
15000000 |
None |
None |
11144.58 |
10613.89 |
2020 |
9621.60 |
None |
None |
Rx0000239 |
Rigel Pharmaceuticals, Inc. |
03/31/2025 |
71332000690 |
GAVRETO 100MG 90 CAPS |
01/03/2025 |
1001.15 |
17718.00 |
11/01/2036 |
Single Source Drug |
None |
None |
None |
1 |
Pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, commercial and government rebates, patient support, overall research and development costs |
None |
This WAC increase is not necessitated by a change or improvement in the prescription drug. |
None |
02/22/2024 |
BluePrint Medicines Corporation |
15000000 |
None |
None |
16716.85 |
15920.81 |
2020 |
14432.40 |
None |
None |
Rx0000239 |
Rigel Pharmaceuticals, Inc. |
03/31/2025 |
71332000101 |
TAVALISSE TAB 100MG 60 TABS |
01/03/2025 |
730.00 |
15530.00 |
07/27/2032 |
Single Source Drug |
None |
None |
None |
1 |
Pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, commercial and government rebates, patient support, overall research and development costs |
None |
This WAC increase is not necessitated by a change or improvement in the prescription drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000239 |
Rigel Pharmaceuticals, Inc. |
03/31/2025 |
71332000201 |
TAVALISSE Tab 150MG 60 TABS |
01/03/2025 |
730.00 |
15530.00 |
07/27/2032 |
Single Source Drug |
None |
None |
None |
1 |
Pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, commercial and government rebates, patient support, overall research and development costs |
None |
This WAC increase is not necessitated by a change or improvement in the prescription drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |